Your search for "newcastle disease" return 105 results.
Innovation Award for Sleeping Sickness Control campaign's partners >
SOS partners COCTU and COVAB, Makerere given Innovation Award for sleeping sickness control campaign
Ceva and Sogeval in exclusive negotiations to create a global leader in animal health >
Ceva and Sogeval (a subsidiary of Sofiprotéol), based in Laval announce the opening of exclusive negotiations to create a future alliance.
Long term agreement with Jinyu Baoling to produce brucellosis vaccines in China >
Ceva concludes long term agreement with Jinyu Baoling to produce brucellosis vaccines in China
Ceva launches new Vectormune ® website >
Website provides educational resources for poultry professionals, as well as comprehensive information about their vector vaccines range.
Ceva stresses the need for more INNOVATION in the hatchery to drive growing global demand for poultry meat >
Company launches Cevac IBird ® a live, attenuated IB vaccine, to add to its portfolio of 16 new technology vaccines
Ceva stresses the need for more INNOVATION in the hatchery to drive growing global demand for poultry meat >
Company launches Cevac IBird ® a live, attenuated IB vaccine, to add to its portfolio of 16 new technology vaccines
Ceva’s growth continues despite difficult market conditions >
Libourne, France, 22 July, 2013: Consolidated sales of the Ceva Group reached €310m in the first 6 months of 2013, up by 2%, 4.2% on the previous year at a constant perimeter and exchange rates. C...
Signature of a scientific collaboration protocol about avian influenza with South China Agricultural University >
Paris, May 29th 2013 1- Ceva, a socially responsible company committed to the well-being of the planet Ceva Santé Animale is a multi-national French based animal health company that counts over 3000 e...
New Technology Vaccine Symposium - Miami >
Ceva shares global field experiences through New Technology Vaccine Symposium held in the US. Innovation in the hatchery will drive productivity gains
Ceva records double digit growth for 3rd. successive year >
14% growth pushes sales beyond 600 M€ for first time